Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Novartis
Nested Therapeutics, Inc
National Cancer Institute (NCI)
Pfizer
Pfizer
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Cancer Research UK
Cancer Research UK
Ikena Oncology
National Cancer Institute (NCI)
Aminex Therapeutics, Inc.
University of Southern California
Memorial Sloan Kettering Cancer Center
Deciphera Pharmaceuticals, LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Genexine, Inc.
Polaris Group
Case Comprehensive Cancer Center
Shenzhen BinDeBio Ltd.
Center Trials & Treatment
BBB-Therapeutics B.V.
National Cancer Institute (NCI)
GE Healthcare
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
Duke University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
TransMolecular